Mosges R, et al. - Researchers evaluated if a cumulative dose of 170 μg Lolium perenne (LPP) administered subcutaneously over 3 weeks is clinically efficacious and safe in adults with grass pollen rhinoconjunctivitis. They mainly focused on the combined symptom and medication score (CSMS) measured over the peak pollen season among patients randomly allocated (1:2 ratio) to receive eight subcutaneous injections of placebo or 170 μg LPP administered in increasing doses in four visits over 3 weeks. They also examined reactivity to conjunctival provocation test (CPT) and quality of life (QOL). Findings revealed the general safety and good tolerability of Lolium perenne pollen peptides, along with efficacy in significantly attenuating seasonal symptoms, when administered over 3 weeks before the grass pollen season.